Varian Medical Systems and Elekta Settle Patent Litigation
Get Alerts VAR Hot Sheet
Join SI Premium – FREE
PALO ALTO, Calif., April 3, 2017 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) today announced that it has reached a confidential settlement agreement with Elekta (EKTA-B) to end ongoing patent litigation involving technology used for radiation oncology and the treatment of cancer. Varian and Elekta resolved the multi-year disputes in the United States, Germany, and the United Kingdom, including the suit brought by Elekta AB and William Beaumont Hospital, with no payments exchanged by the plaintiffs and defendants and no future financial obligations. The two companies have been in litigation since 2015.
About Varian Medical SystemsVarian Medical Systems focuses energy on saving lives and is the world's leading manufacturer of medical devices and software for treating and managing cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,400 people at sites around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.
Press Contact Spencer SiasVarian Medical Systems+1 (650) 424-5782 [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/varian-medical-systems-and-elekta-settle-patent-litigation-300433725.html
SOURCE Varian Medical Systems
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- New Anglia University Examines How International Clinical Networks Are Expanding Opportunities for British Medical Students
- New research: 71% of energy leaders globally say capital is available, but only 29% see enough investable energy projects due to constraints and interdependencies
- Semos Cloud recognized as a winner of the partner agent race to SAP TechEd 2026 with AI innovation for people and culture
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share